Raymond James initiates Outperform rating on Kymera Therapeutics
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
11:24:22 AM UTC
SquawkNews
Kymera Therapeutics Price Target Announced at $140.00/Share by Raymond James